Endometrial hiperplazi ve adenokarsinomlarda progesteron reseptörlerinin durumu
Amaç: Bu çalışmada endometrial hiperplazi ve endometrial adenokarsinom teşhisi konulmuş vakalarda endometriumdaki östrojen reseptörlerinin (ER) özelliklerini karşılaştırmayı amaçladık. Yöntem: Basit tipte endometrial hiperplazi tanısı almış 15 vaka ile iyi diferansiye (greyd I) endometrial adenokarsinom tanısı almış 15 vakada peroksidaz-antiperoksidaz metodu ile parafin blok kesitlerine spesifik fare monoklonal ER antikorları uygulandı ve dokulardaki ER'leri araştırıldı. Bulgular: ER'lerin spesifik boyanması sadece çekirdekte sınırlı idi; sitoplazmada boyanma tespit edilmedi. Endometrial hiperplazi vakalarının tamamında epitel hücrelerinin çekirdeklerinde ER pozitifliği mevcut iken bu oran endometrial adenokarsinom vakalarında % 80 olarak bulundu. Her iki grupta da stromal hücrelerde epitel hücrelerine göre daha düşük derecede ER pozitifliği mevcuttu. Sonuç: Endometrial adenokarsinom vakalarında steroid reseptörlerinin durumunun değerlendirilmesi hastaya uygulanacak tedavi yönteminin seçilmesine yandımcı olabilir.
Progesterone receptors in hyperplastic and carcinomatous endometria
Objective: The aim of this study was to compare characteristics of estrogen receptors (ER) in endometrium of cases of endometrial hyperplasia and adenocarcinoma. Methods: 15 cases with simple endometrial hyperplasia and 15 cases with grade I endometrial adenocarcinoma were evaluated. Specific monoclonal mouse antibody against estrogen receptor was used with peroxidase-antiperoxidase technique to localize estrogen receptors in paraffin embedded sections. Results: Specific staining for ER was limited to nuclei; no specific cytoplasmic staining was observed. ER was positive in the nuclei of epithelial cells in all of the patients with endometrial hyperplasia and in 80% of the patients with endometrial adenocarcinomas. In both groups, ER was less positive in the nuclei of stromal cells than in the nuclei of epithelial cells. Conclusion: Evaluating estrogen receptors in the cases of endometrial adenocarcinoma can be helpful for selecting treatment method.
___
- Fox H. Haines and Taylor’s obstetrical and gynecological pathology. Vol I, 3rd ed. New York: Churchill-Livingstone; 1987. Kurmann RJ, Kumaski PF. The behavior of endometrial hyperplasia. Cancer 1985;56:403-12. Novak Edmund R, Woodruf JD. Novak's gynecologic and obstetric pathology. 8th ed. Philadelphia: WB Saunders Comp; 1979. Rosai J. Ackerman's surgical pathology. Vol II, 7th ed. Washington: CV Mosby Comp; 1989. Sternberg SS. Diagnostic surgical pathology. Vol II, 2nd ed. New York: Raven Press; 1994. Boman K, Isomaa V. Immunocytochemical study of the human 17 b-hydroxysteroid dehidrogenase and steroid receptors in endometrial adenocarcinoma. Cancer 1992;70:1551-5. Kauppila A, Vihko R. Cytosol estrogen and progestin receptors in endometrial carcinoma of patients treated with surgery, radiotherapy and progestin. Cancer 1982;50:2157-62. Carcangiu ML, Chambers JT. Immunocytochemical evalution of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Am J Clin Pathol 1990;94:247-54. Creasman WT, McCarty KS, Soper JT. Endometrial adenocarcinoma estrogen receptor content: Association of clinicopathologic features with immunohistochemical analysis compared with standard biochemical methods. Am J Obstet Gynecol 1987;157:924-31. Segreti EM, Novotny DB. Endometrial cancer: Histologic correlates of immunohistochemical localization of progesterone receptor and estrogen receptor. Obstet Gynecol 1989;73:780. Coffer A, King RJB. Immunoradiometric studies with monoclonal antibody against a component related to human estrogen receptor. Cancer Res 1985;45:3694-8. Novotny B, McCarty KS. Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res 1986;46:5419-25. Pertschuk LP, Beddoe AM. Immunohistochemical assay of estrogen receptors in endometrial carcinoma with monoclonal antibodies. Cancer 1986;57:1000-4. Press MF, King WJ. Immunohistochemical assessment of estrogen receptor distribution in the human endometrium during the menstrual cycle. Lab Invest 1984;51:495-503. Applanat MP, Milgrom E. Immunocytochemical study with monoclonal antibodies to progesterone receptor in human breast tumors. Cancer Res 1987;47:2652-61. Hort O, Kwan PWL, Delellis A. Immunohistochemistry of estrogen receptor protein in paraffin sections. Am J Clin Pathol 1988;90:559-63. McCarty KS, Miller LS. Estrogen receptor analyses correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arc Pathol Lab Med 1985;109:716-21. Bergeron C, Ferenczy A. Immunocytochemical study of progesterone receptors in the human endometrium during the menstrual cycle. Lab Invest 1988:59:862-9. Evans LH, Marthin JD. Estrogen receptor concentration in normal and pathological human uterine tissues. J Clin Endocrinol Metab 1974;38:23-32. Arısan K. Kadın Hastalıkları (Jinekoloji). İstanbul: 1983. İplikçi A. Kadın genital sistem ve meme hastalıkları patolojisi. İstanbul: İÜ Yayınları; 1990. Sözen U, Maral İ, Balık E, Bayol Ü, Ortaç R. Endometrial hiperplazide siklik progesteron tedavisi ve histopatolojik sonuçların değerlendirilmesi. Jinekolojik Obstetrik 1993;3:232-8. Haukamaa M, Karjalaimen O. Invitro binding of progesterone by hyperplastic, atrophic and carcinomatous endometrium. Am J Obstet Gynecol 1971;111:205-10. Coffer A, King RJB. monoclonal antibodies against a component related to soluble estrogen receptor. Cancer Res 1985;45:3686-93. Ehrlich CE, Young PCM. Cytoplasmic progesterone and estradiol receptors in normal, hyperplastic and carcinomatous endometria: Therapeutic implications. Am J Obstet Gynecol 1981;141:539-46. Papadimitriou CS, Athanasiadou S. Immunohistochemical detection of estrogen receptors on paraffin section of normal, hyperplastic and carcinomatous endometrium. Oncology 1992;49:196-202. Creasman WT. Prognostic significance of hormone receptors in endometrial cancer. Cancer 1993;71:1467-71. Creasman WT, Soper JT. Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma. Am J Obstet Gynecol 1985;151:922-32. Ehrlich CE, Young PCM. Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. Am J Obstet Gynecol 1988;158:796-807. Liao BS, Twiggs LB. Cytoplasmic estrogen and progesterone receptors as prognostic parameters in primer endometrial carcinoma. Obstet Gynecol 1986;67:463-7. Mortel M, Zaina R. Heterogeneity and progesterone receptor with monoclonal antibodies to the human progestin receptor. Endocrinology 1988;122:1165-75.